Medical Developments International Ltd.
Medical Developments International (MDI) is a global leader in acute pain and respiratory products, committed to transforming lives through innovative medical devices. With a history spanning over 50 years, MDI develops, manufactures, and distributes medical devices that improve patient care worldwide. The company has a strong focus on research and development, quality assurance, and supply chain solutions, supporting growth in the Australian and international healthcare markets. MDI's mission is to advance the treatment of acute pain and respiratory illness, leveraging industry-leading innovation and strategic partnerships to expand access to essential medicines and devices.
Industries
Nr. of Employees
small (1-50)
Medical Developments International Ltd.
4 Caribbean Drive Scoresby VIC 3179 Australia
Patents
Products
Inhaled non-opioid analgesic delivery system
An inhalation-based analgesic delivery system intended for short-acting pain relief in emergency, ambulance and procedural settings.
Respiratory devices (spacers and inhaler systems)
Devices and spacers intended to support inhaled therapy administration for asthma and chronic obstructive pulmonary disease (COPD).
Inhaled non-opioid analgesic delivery system
An inhalation-based analgesic delivery system intended for short-acting pain relief in emergency, ambulance and procedural settings.
Respiratory devices (spacers and inhaler systems)
Devices and spacers intended to support inhaled therapy administration for asthma and chronic obstructive pulmonary disease (COPD).
Services
Structuring regional licensing and distribution agreements to enable local commercialisation and market access via third‑party partners.
On-site or remote education (inservice), account management support, starter packs and clinical materials to support safe product use.
Preparation and submission of clinical study data to regulatory authorities to support label expansion and market approvals.
Structuring regional licensing and distribution agreements to enable local commercialisation and market access via third‑party partners.
On-site or remote education (inservice), account management support, starter packs and clinical materials to support safe product use.
Preparation and submission of clinical study data to regulatory authorities to support label expansion and market approvals.
Expertise Areas
- Acute pain product development and commercialization
- Respiratory device development and performance testing
- Inhalation drug–device combination development
- Clinical trial execution and clinical data submission
Key Technologies
- High-performance liquid chromatography (HPLC)
- Gas chromatography (GC)
- Fourier-transform infrared spectroscopy (FTIR)
- Aerodynamic particle size distribution (APSD) testing
News & Updates
Announcement of the date for the 2024 AGM, scheduled for 31 October 2024.
Galen has been responsible for marketing and distribution of Penthrox® in the UK and Ireland since 2014. The agreement has been extended to 2027, with potential for expanded indications to include children as young as 6 years old.
MDI has entered into a licensing agreement with Labatec for marketing and distribution of Penthrox® in Switzerland, supporting access to treatment.
Ethypharm will handle marketing and distribution of Penthrox® in France starting July 2025, expanding access to the product in Europe.
Partnership with Ethypharm to distribute Penthrox® in France, starting July 2025.
Galen has been responsible for marketing and distribution of Penthrox® in the UK and Ireland since 2014. The agreement has been extended to 2027, with potential for expanded indications to include children as young as 6 years old.
Announcement of the date for the 2024 AGM, scheduled for 31 October 2024.
Galen has been responsible for marketing and distribution of Penthrox® in the UK and Ireland since 2014. The agreement has been extended to 2027, with potential for expanded indications to include children as young as 6 years old.
MDI has entered into a licensing agreement with Labatec for marketing and distribution of Penthrox® in Switzerland, supporting access to treatment.
Ethypharm will handle marketing and distribution of Penthrox® in France starting July 2025, expanding access to the product in Europe.
Partnership with Ethypharm to distribute Penthrox® in France, starting July 2025.
Galen has been responsible for marketing and distribution of Penthrox® in the UK and Ireland since 2014. The agreement has been extended to 2027, with potential for expanded indications to include children as young as 6 years old.